Filing Details
- Accession Number:
- 0001179110-19-001699
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-11 16:23:49
- Reporting Period:
- 2019-02-07
- Accepted Time:
- 2019-02-11 16:23:49
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1235010 | Momenta Pharmaceuticals Inc | MNTA | Biological Products, (No Disgnostic Substances) (2836) | 043561634 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1755118 | Ian Fier | C/O Momenta Pharmaceuticals, Inc. 301 Binney Street Cambridge MA 02142 | Chief Mfg And Program Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-02-07 | 713 | $0.00 | 80,985 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-02-08 | 251 | $11.52 | 80,734 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2019-02-07 | 713 | $0.00 | 713 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
5,700 | No | 4 | M | Direct |
Footnotes
- Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017.
- This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- Restricted Stock Units convert into common stock on a one-for-one basis.
- Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.